The News Review:
- Matrix ties up with Canadian co for contract research
- Xiangya Medical University and Yale
- Understanding The Mechanisms f Cancer In rder To Develop More…
- Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at…
- SA to host conference about brain injuries
Matrix ties up with Canadian co for contract research
Hindu Business Line – Aug 12, 2007
11 The Hyderabad-based Matrix Group and the Canada-based Ethica Clinical Research Inc have formed a joint venture Ethicamatrix Clinical Research Pvt Ltd for contract research. “Ethicamatrix will function as a full service Contract Research rganisation (CR). We will take up ethical clinical research on drugs biologics medical devices and natural health products” Mr V. Siva Prasad Chief Executive fficer Matrix Group told Business Line here on Saturday. “This is 50:50 joint venture partnership and we will invest about Rs 10 crore in the next one year in strengthening our operations” he said. The firm currently has 30 clinical research analysts. Efforts were on to tie-up with leading hospitals including Deccan Institute of Medical Sciences Hyderabad and Sri Venkateswara Institute of Medical Science Tirupati he added… Siva Prasad Chief Executive fficer Matrix Group told Business Line here on Saturday. “This is 50:50 joint venture partnership and we will invest about Rs 10 crore in the next one year in strengthening our operations” he said. The firm currently has 30 clinical research analysts. Efforts were on to tie-up with leading hospitals including Deccan Institute of Medical Sciences Hyderabad and Sri Venkateswara Institute of Medical Science Tirupati he added. Mr Murray Jensen Director (Clinical Research Affairs) Ethica Clinical Research Inc said Ethicamatrix would focus on clinical study management study monitoring and investigative training among others. thehindubusinessline.
Xiangya Medical University and Yale
çº¢ç’ – Aug 12, 2007
The government evaluated the lab in 1991 and the lab is authorized to be opened to researchers home and abroad. ¡¡The research in the lab covers study of the genetic background and pathogenesis of the hereditary disease using the techniques of cytogenetics molecular cytogenetics and molecular genetics for the diagnosis prevention and treatment of hereditary disease. The long-term project in 2010 and the tenth five-year program were determined by the Academic Committee as follows: (1)New achievement on gene cloning gene function and the prevention of hereditary disease; (2)Complete clinical research on the new vector for gene therapy and establish gene therapy methods for several hereditary diseases; (3)Creative achievement on the molecular mechanism of intracellular protein trafficking; (4)Initiate the project on the isolation and the directional differentiation of embryonic stem cell for therapeutic cloning; (5)Exploitation of one or two gene engineering products. ¡¡Since 1991 the laboratory has undertaken 60 projects on the grants of the province the Ministry of Public Health the state and the international collaboration including one 85 project one 863 general project two 863 major projects one 973 project five major projects from Nature Science Foundation of China four cooperative projects with SmithKline Beecham. 3374 million per year in recent five years. The main researches focus on gene cloning gene function and gene therapy of hereditary disease.
Understanding The Mechanisms f Cancer In rder To Develop More…
Medical News Today – Medical News Today (press release) – Aug 12, 2007
—————————-The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal Quebec the institute is the research arm of the MUHC a university health center affiliated with the Faculty of Medicine at McGill University. The institute supports over 500 researchers nearly 1000 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge innovation and technology and is inextricably linked to the clinical programs of the MUHC ensuring that patients benefit directly from the latest research-based knowledge. For further details visit:.
Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at…
FinanzNachrichten.de – Aug 12, 2007
Ligand’s Vice President of Clinical Research. ”In addition a pharmacokinetic profile of LGD-4665 allows not only for a once-a-day dosing but due to its long half-life potentially for a weekly dosing regimen as well. Based on its strong potency convenience and potential for dosing flexibility we believe that LGD-4665 could be used as treatment for a wide variety of diseases associated with thrombocytopenia including hepatitis C chemotherapy-induced thrombocytopenia (CIT) myelodysplastic syndromes (MDS) idiopathic thrombocytopenic purpura (ITP) and several other cancers and liver diseases. LGD-4665 Study Design The placebo-controlled double-blind dose-escalating Phase I clinical trial was conducted at a single center in 106 healthy male subjects. In the single dose portion of the trial six subjects were randomized in the several dose cohorts to receive either a single dose of LGD-4665 or placebo (in a 2:1 ratio).
SA to host conference about brain injuries
San Antonio Express – Aug 12, 2007
It is not the same life but he has his own life. " Families like the Burtons will be in San Antonio next weekend for a two-day conference covering a wide range of issues related to brain injuries. Speakers will talk about the latest clinical research recent state legislation and the nuts and bolts of family advocacy. The conference is organized by the Brain Injury Association of Texas and will be held Saturday and Sunday at Holiday Inn Select Airport at 77 N. It is open to the public.
